Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Upgrade
Lexicon upgraded to Buy from Hold at Gabelli » 09:13
11/18/20
11/18
09:13
11/18/20
09:13
LXRX

Lexicon

$1.82 /

+0.535 (+41.63%)

Gabelli analyst Kevin…

Gabelli analyst Kevin Kedra upgraded Lexicon to Buy from Hold.

ShowHide Related Items >><<
LXRX Lexicon
$1.82 /

+0.535 (+41.63%)

LXRX Lexicon
$1.82 /

+0.535 (+41.63%)

10/14/20 JPMorgan
Lexicon resumed with an Underweight at JPMorgan
07/21/20 Stifel
Stifel says incremental value of Lexicon data 'likely negligible at best'
12/20/19 Stifel
Stifel says Lexicon 'missed opportunity' with sotagliflozin data
12/11/19 Gabelli
Lexicon downgraded to Hold on valuation at Gabelli
LXRX Lexicon
$1.82 /

+0.535 (+41.63%)

LXRX Lexicon
$1.82 /

+0.535 (+41.63%)

Tuesday
Hot Stocks
Lexicon announces SOLOIST, SCORED studies achieve primary endpoint » 08:01
11/17/20
11/17
08:01
11/17/20
08:01
LXRX

Lexicon

$1.29 /

+0.015 (+1.18%)

Lexicon announced that…

Lexicon announced that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints by demonstrating statistically significant reductions in total cardiovascular deaths, hospitalizations for heart failure and urgent heart failure visits in patients treated with sotagliflozin as compared with placebo. In the SOLOIST study, the primary endpoint was achieved with a hazard ratio of 0.67 in people with type 2 diabetes and a recent hospitalization for worsening heart failure. In the SCORED study, the primary endpoint was achieved with a hazard ratio of 0.74 in people with type 2 diabetes and chronic kidney disease with an estimated glomerular filtration rate, or eGFR, of 25 to 60 ml/minute per 1.73 m of body-surface area. The key results from SOLOIST and SCORED were presented at the Late-Breaking Science Session of the American Heart Association, or AHA, Scientific Sessions and simultaneously published in The New England Journal of Medicine, or NEJM, in two separate articles.

ShowHide Related Items >><<
LXRX Lexicon
$1.29 /

+0.015 (+1.18%)

LXRX Lexicon
$1.29 /

+0.015 (+1.18%)

10/14/20 JPMorgan
Lexicon resumed with an Underweight at JPMorgan
07/21/20 Stifel
Stifel says incremental value of Lexicon data 'likely negligible at best'
12/20/19 Stifel
Stifel says Lexicon 'missed opportunity' with sotagliflozin data
12/11/19 Gabelli
Lexicon downgraded to Hold on valuation at Gabelli
LXRX Lexicon
$1.29 /

+0.015 (+1.18%)

LXRX Lexicon
$1.29 /

+0.015 (+1.18%)

Over a week ago
Earnings
Lexicon reports Q3 EPS 71c, consensus 26c » 06:37
10/29/20
10/29
06:37
10/29/20
06:37
LXRX

Lexicon

$1.23 /

-0.095 (-7.17%)

Reports Q3 revenue $6.6M,…

Reports Q3 revenue $6.6M, consensus $16.87M. "In Q3, we streamlined our operations to prioritize our focus on our advancement of LX9211, a promising drug candidate with potential to become a treatment option for the millions of people living with neuropathic pain. Most people suffering with neuropathic pain experience only limited success with available therapies while enduring substantial side effects," said CEO Lonnel Coats. "We have commenced our first Phase 2 study in diabetic peripheral neuropathic pain and plan to commence our second Phase 2 study in post-herpetic neuralgia shortly with results for both studies expected by the end of next year."

ShowHide Related Items >><<
LXRX Lexicon
$1.23 /

-0.095 (-7.17%)

LXRX Lexicon
$1.23 /

-0.095 (-7.17%)

10/14/20 JPMorgan
Lexicon resumed with an Underweight at JPMorgan
07/21/20 Stifel
Stifel says incremental value of Lexicon data 'likely negligible at best'
12/20/19 Stifel
Stifel says Lexicon 'missed opportunity' with sotagliflozin data
12/11/19 Gabelli
Lexicon downgraded to Hold on valuation at Gabelli
LXRX Lexicon
$1.23 /

-0.095 (-7.17%)

LXRX Lexicon
$1.23 /

-0.095 (-7.17%)

Over a month ago
Conference/Events
JPMorgan SMid biotech analyst to hold analyst/industry conference call » 09:44
10/14/20
10/14
09:44
10/14/20
09:44
CRNX

Crinetics

$16.83 /

+ (+0.00%)

, RUBY

Rubius Therapeutics

$5.72 /

-0.03 (-0.52%)

, KLDO

Kaleido Biosciences

$10.56 /

+0.06 (+0.57%)

, MGTA

Magenta Therapeutics

$7.66 /

+ (+0.00%)

, APTX

Aptinyx

$3.86 /

+0.01 (+0.26%)

, AXLA

Axcella Health

$5.06 /

+0.03 (+0.60%)

, LXRX

Lexicon

$1.48 /

+ (+0.00%)

SMid Biotech Analyst Fye…

SMid Biotech Analyst Fye discusses the re-launch of the SMid-Biotech Sector including CRNX, RUBY, KLDO, MGTA, APTX, AXLA and LXRX on an Analyst/Industry conference call to be held on October 14 at 10 am.

ShowHide Related Items >><<
RUBY Rubius Therapeutics
$5.72 /

-0.03 (-0.52%)

MGTA Magenta Therapeutics
$7.66 /

+ (+0.00%)

LXRX Lexicon
$1.48 /

+ (+0.00%)

KLDO Kaleido Biosciences
$10.56 /

+0.06 (+0.57%)

CRNX Crinetics
$16.83 /

+ (+0.00%)

AXLA Axcella Health
$5.06 /

+0.03 (+0.60%)

APTX Aptinyx
$3.86 /

+0.01 (+0.26%)

CRNX Crinetics
$16.83 /

+ (+0.00%)

10/14/20 JPMorgan
Crinetics resumed with a Neutral at JPMorgan
08/07/20 Piper Sandler
Crinetics likely to report positive Phase 2 results in Q4, says Piper Sandler
05/11/20 Cantor Fitzgerald
Crinetics price target raised to $38 from $28 at Cantor Fitzgerald
05/08/20 Piper Sandler
Piper Sandler continues to recommend Crinetics after paltusotine data
RUBY Rubius Therapeutics
$5.72 /

-0.03 (-0.52%)

10/14/20 JPMorgan
Rubius Therapeutics resumed with a Neutral at JPMorgan
03/13/20 Morgan Stanley
Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program
03/13/20 Guggenheim
Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim
03/13/20 SVB Leerink
Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation
KLDO Kaleido Biosciences
$10.56 /

+0.06 (+0.57%)

10/14/20 JPMorgan
Kaleido Biosciences resumed with an Underweight at JPMorgan
09/18/20 Chardan
Seres Therapeutics downgraded to Neutral from Buy at Chardan
05/21/20 Morgan Stanley
Morgan Stanley downgrades Kaleido to Equal Weight amid delays for key programs
05/21/20 Morgan Stanley
Kaleido downgraded to Equal Weight from Overweight at Morgan Stanley
MGTA Magenta Therapeutics
$7.66 /

+ (+0.00%)

10/14/20 JPMorgan
Magenta Therapeutics resumed with an Overweight at JPMorgan
06/08/20 Goldman Sachs
Magenta Therapeutics upgraded to Buy from Neutral at Goldman Sachs
01/15/20 BTIG
BTIG sees 'no real reason' for Magenta Therapeutics sell-off
12/06/19 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
APTX Aptinyx
$3.86 /

+0.01 (+0.26%)

10/14/20 JPMorgan
Aptinyx resumed with a Neutral at JPMorgan
07/01/20 Truist
Aptinyx initiated with a Buy at SunTrust
07/01/20 Truist
Aptinyx initiated with a Buy at SunTrust
05/08/20
Fly Intel: Top analyst initiations
AXLA Axcella Health
$5.06 /

+0.03 (+0.60%)

10/14/20 JPMorgan
Axcella Health resumed with a Neutral at JPMorgan
09/30/20 Piper Sandler
Axcella publication brings focus to broad applicability of EMM, says Piper
09/25/20 B. Riley Securities
Axcella Health initiated with a Buy, $14 target at B. Riley FBR
09/25/20 B. Riley Securities
Axcella initiated with a Buy at B. Riley FBR
LXRX Lexicon
$1.48 /

+ (+0.00%)

10/14/20 JPMorgan
Lexicon resumed with an Underweight at JPMorgan
07/21/20 Stifel
Stifel says incremental value of Lexicon data 'likely negligible at best'
12/20/19 Stifel
Stifel says Lexicon 'missed opportunity' with sotagliflozin data
12/11/19 Gabelli
Lexicon downgraded to Hold on valuation at Gabelli
RUBY Rubius Therapeutics
$5.72 /

-0.03 (-0.52%)

MGTA Magenta Therapeutics
$7.66 /

+ (+0.00%)

LXRX Lexicon
$1.48 /

+ (+0.00%)

KLDO Kaleido Biosciences
$10.56 /

+0.06 (+0.57%)

CRNX Crinetics
$16.83 /

+ (+0.00%)

AXLA Axcella Health
$5.06 /

+0.03 (+0.60%)

APTX Aptinyx
$3.86 /

+0.01 (+0.26%)

  • 25
    Jun
  • 02
    Jun
  • 14
    May
  • 15
    Apr
  • 10
    Jan
MGTA Magenta Therapeutics
$7.66 /

+ (+0.00%)

LXRX Lexicon
$1.48 /

+ (+0.00%)

KLDO Kaleido Biosciences
$10.56 /

+0.06 (+0.57%)

CRNX Crinetics
$16.83 /

+ (+0.00%)

Initiation
Lexicon resumed with an Underweight at JPMorgan » 08:31
10/14/20
10/14
08:31
10/14/20
08:31
LXRX

Lexicon

$1.48 /

-0.005 (-0.34%)

JPMorgan analyst Jessica…

JPMorgan analyst Jessica Fye resumed coverage of Lexicon with an Underweight rating and no price target. Chronic pain is a large opportunity but LX9211's novel mechanism will have to be proven out in clinical studies, Fye tells investors in a research note. The analyst does not expect the negative sentiment on the stock to reverse in the near term.

ShowHide Related Items >><<
LXRX Lexicon
$1.48 /

-0.005 (-0.34%)

LXRX Lexicon
$1.48 /

-0.005 (-0.34%)

07/21/20 Stifel
Stifel says incremental value of Lexicon data 'likely negligible at best'
12/20/19 Stifel
Stifel says Lexicon 'missed opportunity' with sotagliflozin data
12/11/19 Gabelli
Lexicon downgraded to Hold on valuation at Gabelli
12/11/19 Gabelli
Lexicon downgraded to Hold from Buy at Gabelli
LXRX Lexicon
$1.48 /

-0.005 (-0.34%)

LXRX Lexicon
$1.48 /

-0.005 (-0.34%)

Hot Stocks
Lexicon begins patient dosing in Relief-DPN-1 Phase 2 study » 08:03
09/04/20
09/04
08:03
09/04/20
08:03
LXRX

Lexicon

$1.61 /

-0.065 (-3.89%)

Lexicon Pharmaceuticals…

Lexicon Pharmaceuticals announced the commencement of patient dosing with blinded study drug in RELIEF-DPN-1, a Phase 2 randomized, placebo-controlled, multi-center clinical study of LX9211 for the treatment of diabetic peripheral neuropathic pain. LX9211 is a potent oral small molecule inhibitor of adaptor associated kinase 1, AAK1. "We are pleased to progress with patient dosing in our first proof-of-concept study of LX9211, in patients with diabetic peripheral neuropathic pain," said Praveen Tyle, Ph.D., executive vice president of research and development. "Based on preclinical data, we believe that LX9211 has the potential to significantly reduce pain response without addictive properties while offering a novel therapeutic approach to neuropathic pain through inhibition of AAK1. We are preparing for an additional Phase 2 study in post-herpetic neuralgia that is expected to commence later this year and are evaluating opportunities in other areas of neuropathic pain, based on promising results in multiple preclinical models and a favorable Phase 1 clinical safety profile."

ShowHide Related Items >><<
LXRX Lexicon
$1.61 /

-0.065 (-3.89%)

LXRX Lexicon
$1.61 /

-0.065 (-3.89%)

07/21/20 Stifel
Stifel says incremental value of Lexicon data 'likely negligible at best'
12/20/19 Stifel
Stifel says Lexicon 'missed opportunity' with sotagliflozin data
12/11/19 Gabelli
Lexicon downgraded to Hold on valuation at Gabelli
12/11/19 Gabelli
Lexicon downgraded to Hold from Buy at Gabelli
LXRX Lexicon
$1.61 /

-0.065 (-3.89%)

LXRX Lexicon
$1.61 /

-0.065 (-3.89%)

Over a quarter ago
Hot Stocks
Lexicon enters into agreement with TerSera for sale of XERMELO » 08:02
07/30/20
07/30
08:02
07/30/20
08:02
LXRX

Lexicon

$1.72 /

-0.025 (-1.43%)

Lexicon Pharmaceuticals…

Lexicon Pharmaceuticals and TerSera Therapeutics LLC announced that they have entered into an asset purchase and sale agreement for the sale to TerSera of Lexicon's rights, title and interest in XERMELO. Pursuant to the terms of the agreement, TerSera will pay Lexicon approximately $159 million in cash at closing, which includes a $155 million upfront payment and approximately $4 million for existing inventory. Lexicon may receive additional development, regulatory and sales milestone payments of up to an aggregate of $65 million for the development and commercialization of telotristat ethyl in patients with biliary tract cancer. Additionally, Lexicon will be eligible to receive mid-teens royalties on net sales of XERMELO in biliary tract cancer. As part of the transaction, TerSera has agreed to assume the currently ongoing TELE-ABC Phase 2 clinical study of XERMELO in biliary tract cancer patients and offer employment to at least 20 Lexicon employees currently dedicated to XERMELO. The transaction is expected to close in the third quarter of 2020, subject to customary closing conditions.

ShowHide Related Items >><<
LXRX Lexicon
$1.72 /

-0.025 (-1.43%)

LXRX Lexicon
$1.72 /

-0.025 (-1.43%)

07/21/20 Stifel
Stifel says incremental value of Lexicon data 'likely negligible at best'
12/20/19 Stifel
Stifel says Lexicon 'missed opportunity' with sotagliflozin data
12/11/19 Gabelli
Lexicon downgraded to Hold on valuation at Gabelli
12/11/19 Gabelli
Lexicon downgraded to Hold from Buy at Gabelli
LXRX Lexicon
$1.72 /

-0.025 (-1.43%)

LXRX Lexicon
$1.72 /

-0.025 (-1.43%)

Hot Stocks
Lexicon aligns business around R&D assets, with focus on Phase 2 LX9211 program » 08:01
07/30/20
07/30
08:01
07/30/20
08:01
LXRX

Lexicon

$1.72 /

-0.025 (-1.43%)

Lexicon Pharmaceuticals…

Lexicon Pharmaceuticals announced that it is realigning its business around its research and development assets, with a focus on its LX9211 neuropathic pain program, now in Phase 2 clinical development. In that regard: Initiation of Phase 2 Clinical Development of LX9211. Lexicon has initiated patient screening in RELIEF-DPN-1, a Phase 2 randomized, placebo-controlled, multi-center clinical study of LX9211 for the treatment of diabetic peripheral neuropathic pain that is expected to enroll approximately 300 patients at 30 U.S. sites. Lexicon is preparing for additional Phase 2 studies of LX9211, a potent oral small molecule inhibitor of adaptor associated kinase 1, in other areas of neuropathic pain based on promising results in multiple preclinical models of neuropathic pain and a favorable Phase 1 clinical safety profile. Sale of XERMELO to TerSera. Lexicon entered into an asset purchase and sale agreement with TerSera Therapeutics LLC for the sale of Lexicon's XERMELO product and related assets for up to $224 million in upfront and milestone payments, consisting of approximately $159 million in cash at closing and up to $65 million in development, regulatory and sales milestones relating to biliary tract cancer, plus eligibility for mid-teens royalties on net sales of XERMELO in biliary tract cancer. As part of the transaction, TerSera has agreed to assume the currently ongoing TELE-ABC Phase 2 clinical study of XERMELO in biliary tract cancer patients and offer employment to at least 20 Lexicon employees currently dedicated to XERMELO. MTS Health Partners, L.P. served as financial advisor and WilmerHale served as legal counsel to Lexicon. Debt Reduction. Lexicon will use the upfront proceeds from the XERMELO sale to substantially reduce its debt, including full repayment of its $150 million secured term loan.

ShowHide Related Items >><<
LXRX Lexicon
$1.72 /

-0.025 (-1.43%)

LXRX Lexicon
$1.72 /

-0.025 (-1.43%)

07/21/20 Stifel
Stifel says incremental value of Lexicon data 'likely negligible at best'
12/20/19 Stifel
Stifel says Lexicon 'missed opportunity' with sotagliflozin data
12/11/19 Gabelli
Lexicon downgraded to Hold on valuation at Gabelli
12/11/19 Gabelli
Lexicon downgraded to Hold from Buy at Gabelli
LXRX Lexicon
$1.72 /

-0.025 (-1.43%)

LXRX Lexicon
$1.72 /

-0.025 (-1.43%)

Hot Stocks
Lexicon to initiates Phase 2 LX9211 study in neuralgia in Q4  07:16
07/30/20
07/30
07:16
07/30/20
07:16
LXRX

Lexicon

$1.72 /

-0.025 (-1.43%)

 
ShowHide Related Items >><<
LXRX Lexicon
$1.72 /

-0.025 (-1.43%)

LXRX Lexicon
$1.72 /

-0.025 (-1.43%)

07/21/20 Stifel
Stifel says incremental value of Lexicon data 'likely negligible at best'
12/20/19 Stifel
Stifel says Lexicon 'missed opportunity' with sotagliflozin data
12/11/19 Gabelli
Lexicon downgraded to Hold on valuation at Gabelli
12/11/19 Gabelli
Lexicon downgraded to Hold from Buy at Gabelli
LXRX Lexicon
$1.72 /

-0.025 (-1.43%)

LXRX Lexicon
$1.72 /

-0.025 (-1.43%)

Hot Stocks
Lexicon to dose first patient in Phase 2 LX9211 study in Q3  07:16
07/30/20
07/30
07:16
07/30/20
07:16
LXRX

Lexicon

$1.72 /

-0.025 (-1.43%)

 
ShowHide Related Items >><<
LXRX Lexicon
$1.72 /

-0.025 (-1.43%)

LXRX Lexicon
$1.72 /

-0.025 (-1.43%)

07/21/20 Stifel
Stifel says incremental value of Lexicon data 'likely negligible at best'
12/20/19 Stifel
Stifel says Lexicon 'missed opportunity' with sotagliflozin data
12/11/19 Gabelli
Lexicon downgraded to Hold on valuation at Gabelli
12/11/19 Gabelli
Lexicon downgraded to Hold from Buy at Gabelli
LXRX Lexicon
$1.72 /

-0.025 (-1.43%)

LXRX Lexicon
$1.72 /

-0.025 (-1.43%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.